Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NDRA vs MYGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MYGN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

MYGN Overall Winner 6-Pillar Tally: NDRA 2 – 4 MYGN Matrix Metrics: NDRA 4 – 6 MYGN

As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas MYGN carries 46.3/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin).

  • Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NDRA vs MYGN
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32
MYGN NASDAQ Head-to-Head Winner
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.59% 1D
Market Cap $542.9M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.68β · 122% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 44.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $5.94 · SMA50: $4.80

6-Pillar Scorecard Institutional Category Breakdown (NDRA 2 – 4 MYGN)

Columns: Metric · NDRA · MYGN
1. Valuation Multiples MYGN
Forward P/E N/M 54.0x
Trailing P/E N/M 54.0x
PEG Ratio N/M 1.40x
EV / Revenue N/M 0.8x
2. Growth & Scale MYGN
Revenue Growth (YoY) +0.0% -1.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $804M
Market Cap $6.6M $542.9M
3. Profitability & Quality NDRA
Gross Margin N/A 68.3%
Operating Margin 0.0% -13.3%
Net Profit Margin 0.0% -16.1%
Return on Equity (ROE) -152.0% -40.2%
4. Balance Sheet & Cash Flow NDRA
Cash Generation (TTM) -$8.0M -$38M
Cash Flow Margin N/A -4.7%
Net Cash / Leverage $104,744 Net Debt (0.26x D/E) $102M Net Debt (0.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYGN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 124.6% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity N/A 81.6% of Rev ($656M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NDRA (4) vs MYGN (6)
Institutional Metric NDRA MYGN Criterion Row Edge
Market Capitalization
Scale
$6.6M $542.9M Larger Scale MYGN
Trailing P/E Ratio
Valuation
N/M 54.0x Lower Multiple MYGN
Forward P/E Ratio
Valuation
N/M 54.0x Lower Multiple MYGN
Revenue Growth (YoY)
Growth
+0.0% -1.5% Higher Growth NDRA
Operating Margin (TTM)
Profitability
0.0% -13.3% Higher Margin NDRA
Net Profit Margin
Profitability
0.0% -16.1% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-152.0% -40.2% Higher ROE MYGN
52-Week Range Position
Momentum
37% ($3–$7) 53% ($3–$8) Stronger Trend MYGN
Beta / 30D Volatility
Risk Regime
0.71β · 48% Vol 0.68β · 122% Vol Lower Realized Risk NDRA
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite MYGN
Trailing 12M Revenue (USD)
Operating Scale
N/A $804M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 68.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.40x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.0M ($104,744 Net Debt (0.26x D/E)) -$38M ($102M Net Debt (0.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +46.7 pp
NDRA: -6.75% · MYGN: +39.95%
3M Horizon MYGN +96.08 pp
NDRA: -2.0% · MYGN: +94.08%
6M Horizon MYGN +70.9 pp
NDRA: -18.3% · MYGN: +52.6%
1Y Horizon MYGN +20.44 pp
NDRA: -32.72% · MYGN: -12.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NDRA Revenue MYGN Revenue NDRA Op. Margin MYGN Op. Margin Margin Leader
FY2018 $0M $740M -146080.5% 16.4% MYGN
FY2019 N/A $850M N/A 0.9% MYGN
FY2020 N/A $560M N/A -52.0% MYGN
FY2021 N/A $690M N/A -27.6% MYGN
FY2022 N/A $680M N/A -20.7% MYGN
FY2023 N/A $750M N/A -34.2% MYGN
FY2024 N/A $840M N/A -14.7% MYGN
FY2025 N/A $820M N/A -47.0% MYGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $542.9M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published

Investor FAQ NDRA vs MYGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Myriad Genetics Inc (MYGN) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NDRA carries a Unified Composite Score of 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin), whereas MYGN carries 46.3/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile MYGN trades in a Markup technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MYGN leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NDRA cumulative revenue shifted N/A while MYGN shifted +10.8%. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.

MYGN screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus MYGN (-40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.68β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.